NEW YORK, Feb. 25, 2017 (GLOBE NEWSWIRE) -- Blake Insomnia Therapeutics Inc. (OTCQB:BKIT) and Sajo Consulting LLC are pleased to announce completion of a joint venture agreement for the development and commercialization of a series of oral drug products to aid in the treatment of insomnia. The joint venture intends to develop products to treat transient insomnia using Blake’s proprietary Zleepax™ formula.

Clinical trials are planned for Q2 2017 pending approval of a New Drug Application in Canada with US and International submissions to follow later.

Sajo Consulting LLC
Sajo designs solutions and strategies in getting products to market faster and smarter. Their research, scientific, regulatory and operational team puts best practice standards to work while building innovative solutions for constantly evolving industries.

Blake Insomnia Therapeutics Inc.

Blake is a New York-based pharmaceutical company devoted to improving night-time and daytime quality of life for people with insomnia. The company’s patent-pending ZLX-1 compound has demonstrated efficacy without producing the side effects identified as the No. 1 problem with current sleep medication. The ZLX-1 compound is marketed under the brand name, Zleepax™.